Stada Arzneimittel AG replaced its top management as the German generic-drug maker faces a decision about whether to allow Bain Capital and Cinven to make a fresh takeover offer after their 5.3 billion-euro ($6 billion) bid failed last week.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
